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ABSTRACT  27 
In a period of generalized economic crisis, it seems particularly appropriate to try to manage a 28 
continuing growing sector such as healthcare in the best possible way. The crucial aim of 29 
optimization of available healthcare resources is obtaining the maximum possible benefit with the 30 
minimum expenditure. This has important social implications, whether individual citizens or tax-31 
funded national health services eventually have to pay the bill. The keyword here is efficiency, 32 
which means either, maximizing the benefit from a fixed sum of money, or minimizing the 33 
resources required for a defined benefit. In order to achieve these objectives, economic evaluation is 34 
a helpful tool. Five different types of economic evaluation exist in the health-care field: cost-35 
minimization, cost-benefit, cost-consequences, cost-effectiveness and cost-utility analysis.  The 36 
objective of this narrative review is to provide an overview of the principal methods used for 37 
economic evaluation in healthcare. Economic evaluation represents a starting point for the 38 
allocation of resources, the decision of the valuable investments and the division of budgets across 39 
different health programs. Moreover, economic evaluation allows the comparison of different 40 
procedures in terms of quality of life and life expectancy, bearing in mind that cost-effectiveness is 41 
only one of multiple facets in the decision making-process. Economic evaluation is important to 42 
critically evaluate clinical interventions and ensure that we are implementing the most cost-effective 43 
management protocols. Clinicians are called to fulfill the complex task of optimizing the use of 44 
resources, and, at the same time, improving the quality of healthcare assistance.45 
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Introduction 46 
Inadequacy of resources is the base of economy. For this reason, the need for optimization of the 47 
available resources appears of primary importance, with the objective of obtaining the maximum 48 
possible benefit with the minimum expenditure. [1]. In a context characterized by frequent cuts to 49 
public spending, the introduction in the health-care field of economic evaluations represents another 50 
intent of reconsidering a sector that consumed 8.8% of Italian gross domestic product (GDP) in 51 
2013, excluding capital expenditure, compared with an OECD (Organization for Economic Co-52 
operation and Development) average of 8.9% [2]. As a reflection of the economic crisis, health 53 
spending continued to shrink in Greece, Italy and Portugal in 2013 [3]. On the contrary, in the last 54 
five years health spending has been growing with a medium rate of 2.5% per year outside Europe 55 
[3]. 56 
 As a consequence, it seems appropriate to try to obtain the best allocation of the finite 57 
available resources at our disposal, in order to guarantee health assistance despite the negative 58 
effects of the economic crisis and to manage in the proper way a continuing growing sector. The 59 
keyword here is efficiency, which means either maximizing the benefit from a fixed sum of money 60 
or minimizing the resources required for a defined benefit [1]. This has important social 61 
implications, whether individual citizens or tax-funded national health services eventually have to 62 
pay the bill. Considering that the healthcare budgets are limited and spending in one area is 63 
unavoidably at the expense of investment in another, efficiency can be interpreted as ensuring that 64 
the benefits obtained exceed the benefits forgone [1]. The latter concept could be also express as 65 
“opportunity cost” [4].  66 
 The objective of this narrative review is to appraise the most recent evidence regarding 67 
economic evaluation and healthcare spending. In fact, the priority is to try to disseminate 68 
information and implement this model within the health community, with the aim of handling 69 
appropriately the financial resources, ensuring the wellbeing of the patient at the first place. 70 
 71 
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Methods 72 
For this review, the best quality evidence was selected with preference given to the most recent and 73 
definitive original articles and reviews. Information was identified by searches of MEDLINE and 74 
references from relevant articles, using combinations of MESH terms “economic evaluation”, “cost-75 
effectiveness analysis”, “cost-effectiveness threshold” “cost-utility analysis”, “efficiency”, “health 76 
economic evaluation”, “health care economic analyses”, “value based medicine”, “NICE” “utility” 77 
and “QALY”. The search was limited to peer-reviewed, full-text articles in the English language. 78 
For most issues, papers published between January 2003 and December 2015 were considered.  79 
 Two authors (FLO and LB) performed an initial screening of the title and abstract to exclude 80 
citations deemed inappropriate for the present narrative review (e.g., experimental studies or 81 
investigational health economic analyses relative to specific treatments). Articles describing the 82 
various approaches with an apparent didactic format were retrieved and assessed. A total of 22 83 
articles that were deemed more informative and clear by both reviewers were eventually selected 84 
and analyzed in detail (1, 2; 5-24). No formal system was adopted to rate the quality of the 85 
evaluated articles. Four reviews (16-19), written by an ophthalmology research group, were 86 
excluded because they were analogous to a fourth included article (15). For a similar reason, we 87 
excluded one review (20) and included another one (1) previously published by the same author. 88 
Two articles (21, 22) were excluded as they explained how to conduct a specific economic analysis, 89 
rather then describe the general characteristics of the various methods. One article (23) was 90 
excluded because it focused on methodological and interpretative aspects of economic analysis. 91 
One article (24) was excluded as only cost-utility and cost-benefit analysis were addressed, but not 92 
cost-effectiveness analysis. A total of 13 articles were eventually included in the present review. 93 
 94 
Types of economic evaluation 95 
In the most commonly used economic evaluations, two interventions, a standard treatment and an 96 
experimental one are compared with the scope of assessing the value of the novel procedure. When 97 
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the latter is more cost-effective than the older one, the novel procedure is obviously chosen; on the 98 
other hand, if the new treatment is more expensive and less effective, the standard one is generally 99 
maintained. Uncertainty arises when the novel treatment is more effective but also more expensive 100 
than the traditional treatment [5]. The scenario becomes more complex when evaluations aim at a 101 
more comprehensive approach, i.e. the comparison between interventions of highly distinct medical 102 
areas. 103 
 Five different types of economic evaluations exist in the health-care field: cost-104 
minimization, cost-benefit, cost-consequences, cost-effectiveness and cost-utility analysis [5] 105 
(Table 1): 106 
- Cost-minimization analysis: in cost-minimization analysis, two or more interventions with 107 
equivalent consequences in terms of benefit are compared [1]. It should ideally be used only when 108 
comparing treatment of equal effectiveness, and it focuses on costs alone to help choosing the 109 
cheapest option [6]. 110 
- Cost-benefit analysis:  it evaluates, in monetary terms, cost and consequences of an intervention 111 
[1]; if the monetary value of an intervention exceeds the cost of the intervention, then the 112 
intervention is acceptable. [7]. This analysis places money values on both inputs (costs) and outputs 113 
(general benefits) of health care and represents the best method to inform allocation decisions 114 
because it consents to compare interventions from highly heterogeneous areas and it is based on a 115 
more comprehensive economic vision of the society [4].  116 
- Cost-consequences analysis: this analysis reflects how decisions are made in the real world. This 117 
approach is often used when various outcomes cannot be condensed into a single measure that 118 
summarizes benefits and costs. For example, in a cost-consequences analysis, the general 119 
practitioner and nurse’s salaries as well as expenditures sustained by patients are considered as 120 
costs, whereas patient health state and satisfaction with treatment are considered as consequences 121 
[1]. 122 
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- Cost-effectiveness analysis (CEA): it is the most widely used analysis and it consents to compare 123 
interventions with a common health outcome. The outcomes could be measured using different 124 
ratios (for example, cost per life year gained or pain free days) [1]. This data should be obtained, 125 
when possible, from clinical trials [8]. CEAs provide a definite answer on a specific comparison, 126 
i.e. it concludes which of the compared options has a more favorable cost-effectiveness profile. 127 
However, a less cost-effectiveness procedure may still be of economic and clinical interest if it is 128 
more effective. To disentangle this possibility, one may rely on the incremental cost effectiveness 129 
ratio (ICER). Specifically, the cost effectiveness ratio (CER) expresses the ratio between the cost of 130 
an intervention (K) and the benefit endpoint gained (E). The ratio K/E describes a treatment’s 131 
marginal costs per gained clinical benefit unit [9]. The ICER allows the comparison between 132 
different interventions for the same pathology. Considering respectively K1 and K2 as the costs of 133 
the standard treatment and the novel one, and E1 and E2 as the benefit endpoints of the two 134 
interventions, the ICER is calculated as [9]: ICER= (K2-K1) / (E2-E1). This ratio permits to define 135 
the additional costs for unit of benefit gained with the new treatment with the possibility of drawing 136 
a “health economical ranking” of the different procedures [9]. 137 
Before comparing the ICERs, it’s fundamental to estimate the cost-effectiveness benchmark, 138 
which expresses the insurer’s maximum willingness to pay (WTP) additional treatment costs per 139 
gained benefit unit. The new treatment will be selected only if the ICER is inferior of the 140 
benchmark [9]. 141 
 The objective is to establish the socially acceptable CER.  As Noyes and Holloway [10] 142 
stated: “Is the additional effects of our new technology compared with the old technology worth the 143 
additional costs?”. The most suitable cost-effectiveness benchmark to be used should be adapted to 144 
the local economical situation but remains highly debated. In the affluent Western world, the 145 
thresholds used are generally more or less equivalent to the gross domestic product (GDP) pro 146 
capita [11]. The National Institute for Health and Clinical Excellence (NICE) has established a cost-147 
effectiveness threshold range between £ 20.000 and £ 30.000 per life year gained.[11] However, 148 
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this kind of analysis could be performed only if the compared interventions use a common unit of 149 
effectiveness, such as cost per life year gained [8]. In addition, a cost-effectiveness analysis might 150 
examine this intervention in terms of quantity and not of quality [8]. 151 
- Cost-utility analysis (CUA): represents an economic evaluation that aims at defining the patient’s 152 
preference for being in a particular health-state [4]. In CUA all the outcomes analyzed are expressed 153 
in terms of QALY (quality adjusted life year). With this method it is possible to compare treatments 154 
used in different stages of a pathology and “opportunity cost” could be measured [4]. It consents to 155 
compare interventions from very different medical disciplines or interventional areas, such as, for 156 
instance a vaccine program and an ambulance referral system. CUAs thus represent a valuable 157 
instrument for taking decisions regarding the allocation of public health resources.   158 
 Contrary to CEA, which analyses a benefit of an intervention only in terms of quantity, 159 
CUA focuses also on quality and include also the preferences of the patient [8]. The effectiveness of 160 
an intervention is measured through its utility value [8] that is ranged between 0 (worst health) and 161 
1 (best health). Then, by multiplying the utility value with the length of time in that state, QALYs 162 
are obtained [8]. Several direct methods exist to calculate the utility value. These include scaling 163 
methods, such as visual analogue system, and choice methods such as the time trade-off and 164 
standard gamble [7].  165 
 The visual analogue system is a linear scale that runs from 0 to 1, 10 or 100, with the higher 166 
values representing the perfect health and 0 the worst health state conceivable (or death) [7]. 167 
Strengths of this method include the easiness of use and the possibility of answering by postal 168 
survey. Moreover, the visual analogue system requires no “trade-off” or choice and the individual 169 
does not have to justify his preference based on monetary, time or health factors [7].  170 
 In the standard gamble, the individual chooses between remaining in the actual state of 171 
chronic health for the rest of his life or picking an uncertain gamble: the possibilities are of being 172 
healthy for the rest of their life, with a probability of p, or immediate death, with a probability of 1-173 
p [10]. The amount of p range from 1.0 to 0.1 until a point of indifference is reached, which defines 174 
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the utility weighting [7]. Advantages of standard gamble are the combination of time, risk and 175 
quality. At the same time these characteristics could represent a weakness, in particular in those 176 
individuals who are time-sensitive and are not prone in taking risky decisions [7].  177 
 The time trade-off system is the method most frequently adopted in the calculation of 178 
QALYs. The individual has to make a choice between two different options: a diminished health 179 
state for a definite time or a full heath state for a shorter life span [7]. Choosing the second 180 
alternative means the sacrifice of a period of life span in exchange of a shorter period of full health 181 
state. For example, if the patient has a life expectancy of 30 years with a specific pathological 182 
condition and decides to reduce it to 15 years with a full health status, the value of his actual health 183 
state is 15/30, i.e. 0.5. This system involves a choice and balances both quality and quantity. 184 
Limitations include the reluctance of exchanging time for health due to personal, philosophical or 185 
religious beliefs [7].  186 
Moreover, the utility value could be measured with indirect methods like questionnaires, 187 
such as Health Utilities Index (HUI), Short-form 6D (SF-6D), and Euro Quality of life 5 188 
Dimensions (EQ-5D) [4]. 189 
 Specific fields that require a CUA include the importance of quality of life as effectiveness 190 
outcome, when the intervention has an impact on both morbidity and mortality, when the 191 
intervention have a multiple range of different outcomes with the aim of producing a single general 192 
outcome for comparison, and when resources must be allocated from a fixed budget [4]. The main 193 
drawback of CUA is the use of measures (QALYs) obtained from population samples, which reflect 194 
the mean value of the general population, that, at the same time, could differ from the specific 195 
interests of the single individual [12].      196 
 197 
Discussion  198 
Key points correlated with the interpretation of the results of an economic evaluation include the 199 
perspective and time horizon, from which the lost and gained costs can be estimate [10]. It should 200 
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be underlined that multiple kinds of perspectives exist: “personal”, “health insurance”, “provider” 201 
and “societal”. The societal perspective takes account of all costs, and is the most suitable one. 202 
Moreover, the societal perspective considers not only the individual patient’s costs but also the 203 
disbursement of the insurance and the National Health System, obtaining a global analysis [10]. 204 
At the same way, the temporal definition of the time horizon, considering that same benefit could 205 
require several years to manifest, appears of fundamental importance [10]. 206 
 Another aspect to consider is the possible creation of an inter-individual conflict of values. 207 
In fact, we have to take into account the impact of individual preferences even when general 208 
population preferences are used to value the benefits of interventions [12]. Furthermore, patient’s 209 
preferences have a rebound on efficacy outcomes, partly due to the inadequate compliance of the 210 
patient to therapy, and to personal psychological factors [12].  211 
 In clinical practice the patient alone is assumed to make the definitive treatment choice, after 212 
receiving all the technical information from the clinician. The figure of the clinician is located in the 213 
middle of this “conflict”, trying to reach a balance between the ideal treatment and the healthcare 214 
budget [12]. In order to overcome this situation, it could be advisable to adopt a two-part decision 215 
process [12]: the detection of the most cost-effective therapy according to mean population values, 216 
and the identification of those treatments that are cheaper than the most cost-effective therapy. 217 
 In the individual patient-doctor relationship, the clinician should describe in detail all the 218 
potential benefits and harms of the available therapeutic alternatives. Fully informed patients are 219 
more likely to choose treatments that show a net benefit [25]. In this regard, the inclusion of the 220 
extra cost for the net benefit of different treatments is fundamental in health care economic 221 
evaluation. 222 
 However, when prescribing a treatment or a procedure, doctors carry a responsibility also 223 
for future patients and for the society at large, especially within a tax-funded national health system. 224 
In fact, when a fixed budget is managed, the use of resources for a category of patients is 225 
unavoidably at the expense of another one. This is known as “opportunity cost”.  226 
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The main objective of any cost evaluation approach is the optimization of the use of finite 227 
resources. Economic evaluation allows a transparent and logical use of a predetermined budget 228 
according to an equity value. In fact, patients have different health conditions that require different 229 
expenditure of resources but, eventually, the result in terms of overall health benefit should be 230 
similar for all patient categories.  231 
 In order to achieve the above objectives, physicians should foster high-value interventions 232 
[26]. The introduction of the concept of value-based medicine in the health service daily practice 233 
appears of fundamental importance also from the economic perspective. Value-based medicine is 234 
obtained by matching the value of an intervention, in terms of QALYs, to evidence-based medicine. 235 
Healthcare providers should not only demonstrate the efficacy of a procedure, but also analyze its 236 
impact on quality of life and on financial resources. The final target of value-based medicine is 237 
maximizing the use of resources, and, at the same time, improving the quality of the healthcare 238 
assistance [15]. 239 
  Value is a word that arouses skepticism, because it is often misunderstood and conceived as 240 
cost reduction [27]. Conversely, value-based medicine could represent the highest form of 241 
efficiency and social equity that health care providers and medical decision-makers could offer to 242 
individual patient and society as a whole, as it constitutes a balance between potential benefits, 243 
potential harms and cost of care, and takes into account patient priorities and preferences [28]. The 244 
medical educational training itself should be restructured with the objective of de-adopting low-245 
value care. According to Schwartz,  “medical students; interns; residents; and fellows must learn 246 
that their mentors and teachers are judging them not only by their ability to properly perform a 247 
procedure but also by their having the expertise in clinical decision making to know when and why 248 
that procedure is medically appropriate” [29]. 249 
 An additional point to stress is the amount of money that the government is prone to pay to 250 
gain an extra unit of benefit. As previously stated in the United Kingdom, the NICE has established 251 
a cost-effectiveness threshold range between £20.000 and £30.000 with the aim of obtaining an 252 
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optimal allocation of limited resources [11]. This threshold should be periodically reassessed to 253 
guarantee that it captures the impact of modifications in efficiency and budget over time [11]. 254 
Maynard and Bloor [13] emphasize the bipolar role of the UK government, as both regulator and 255 
sponsor of the pharmaceutical industry. NICE approves only treatments that have shown to produce 256 
a QALY for an adequate cost, and commissioners are obliged to fund it. In order to obtain a 257 
reimbursement, pharmaceutical industries need to comply with a cost-QALY ratio inferior to 258 
£30.000 [13]. In recent years, pharmaceutical industries have lobbied NICE for the widening of the 259 
cut-off for reimbursement, especially for cancer treatments, that are particular expensive. The risk is 260 
the creation of an unequal logic, in which the cost-effectiveness of a specific treatment is placed in 261 
second line [13]. Moreover, this choice of reimburse only cancer treatments, which cost exceed the 262 
threshold of £30.000, discriminates against other disease which may be equally in need of 263 
additional funding [13]. 264 
 The economic evaluation represents a starting point for the allocation of the resources, the 265 
decision of the valuable investments, and the division of the budget across different health 266 
programs. Moreover, economic evaluations allow the comparison of different procedures in terms 267 
of quality of life and life expectancy, remembering that cost-effectiveness is only one of multiple 268 
facets in the decision-making process. On the other hand, economic evaluations are seen as an 269 
insensible form of utilitarianism and mistrust due to the idea of a “rationing” of the health care 270 
resources. In reality, economic evaluations consent a rational and methodical partition of resources, 271 
in a process of transparency in the decision-making context [14].  272 
 273 
Learning points 274 
• Particularly in a period of economic crisis, maximizing the available health care resources in 275 
order to appropriately manage pre-determined financial budgets, and obtaining the greatest 276 
benefit with the minimum expenditure, according to efficiency, is essential. 277 
• Economic evaluation is the starting point for allocation of finite health care resources.  278 
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• There are five different types of economic evaluation: cost-minimization analysis, cost-279 
benefit analysis, cost-consequences analysis, cost-effectiveness analysis, cost-utility 280 
analysis.  281 
• The main analysis is cost-utility, and the measure is cost per QALY; it focuses on patient’s 282 
preferences and on quality of life. 283 
• In economic evaluation analysis it is crucial to consider different perspectives, i.e., time 284 
horizon, patient compliance, and the extra amount of money that healthcare administrators 285 
are prone to pay with the aim of obtaining the extra benefits. 286 
• The next frontier is value-based medicine, achieved by matching the value of an intervention 287 
with the evidence-based medicine. 288 
• The end-result of economic evaluation in health care is not rationalization of resources but 289 
social equity, that is, providing the best possible medical care to as many as possible people. 290 
 291 
Conclusion 292 
Physicians represent a key figure in the management of resources for the wellbeing of patients, and 293 
they must learn how to allocate in the best possible way the finite budget they have. Therefore, the 294 
role of the physician and the ability in communicating with the patient are of utmost importance. In 295 
fact, the gold standard intervention (on the basis of economic evaluation) may not coincide with the 296 
one chosen by the patient, and the patient’s compliance has a rebound on the effectiveness of the 297 
treatment [12].            298 
 Contrary to common belief, careful administration of resources does not mean 299 
transformation of physicians in economic managers more focused on budgets than on patient health. 300 
Conversely, the combination of available evidence and economic analysis into value-based 301 
medicine represents optimization of the efficiency of the system, supporting the use of a transparent 302 
decision process. The physician has to select the best intervention in terms of efficacy and 303 
effectiveness, using a different amount of resources from patient to patient, tailoring a specific 304 
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treatment for individual cases, respecting at the same time the principles of patient-centered 305 
medicine and equity [26]. 306 
 In spite of the innumerable economic evaluations conducted in recent years, the cornerstones 307 
of these evaluations are rarely performed in clinical practice [14]. The conduction of randomized 308 
controlled trials aimed at assessing the impact of various economic evaluations, could constitute 309 
another step forward in order to draft specific guidelines providing economic indications for 310 
medical choices. 311 
 Economic evaluation in health-care is important to critically assess medical interventions 312 
and guarantee the most cost-effective management protocols [4]. The goal of such an approach is 313 
not to do less or “rationalize” the expenditure, but to allow qualitative improvements in clinical 314 
practice and to offer an equal assistance to as many citizens as possible. 315 
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Types of 
economic 
evaluation 
Measure Advantages Disadvantages Examples of clinical studies 
Cost-
minimization 
analysis 
Difference in monetary 
terms between 
interventions 
Easiness of execution Focused on costs only An Economic Evaluation of Home Versus 
Laboratory-Based Diagnosis of Obstructive 
Sleep Apnea [30] 
In a RCT, given that 3-month clinical outcomes were 
equivalent, the cost of home-based diagnosis of obstructive 
sleep apnea was  $264 less for the payer (95% CI $39, 
$496) compared with laboratory-based diagnosis, whereas a 
difference of  $40 (95% CI, $213 - $142,) in favor of the 
laboratory arm diagnosis was observed from the provider 
perspective.  
Cost-benefit 
analysis 
Net gain or loss in 
monetary terms 
Same measure for benefit 
and costs 
Limited applicability, 
not always possible to 
measure benefit in 
monetary terms (e.g., 
lives saved) 
A cost-benefit analysis of peer coaching for 
overhead lift use in the long-term care sector 
in Canada [31] 
A peer-coaching program for patient ceiling lift use was 
associated with a reduction in the patient-handling injury 
rate of 34% during the program and 56% after the program 
concluded, with an estimated 62 lost-time injury claims 
averted, with a modest monetary cost. The monetary 
benefits and costs to the system were, respectively, 
$748431 and 894000, with a benefit-to-cost ratio of 0.84. 
Cost- Various outcomes  Reflects the complexity  Decision-making is Cost analysis of the Hemodialysis Reliable 
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consequences 
analysis 
(not a single measure) of the real world difficult because there 
is not a single 
measure to compare 
interventions 
Outflow (HeRO) Graft compared to the 
tunneled dialysis catheter [32] 
A 100-patient cohort managed with the HeRO Graft 
experienced 6 fewer failed devices, 53 fewer access-related 
infections, and 67 fewer device thrombosis compared to 
patients managed with tunneled dialysis catheter (TDCs). 
Although the initial device and placement costs for the 
HeRO Graft are greater than those for TDCs, savings from 
the lower incidence of device complications and longer 
effective device patency reduces these costs. Overall net 
annual costs are £2600 for each HeRO Graft-managed 
patient compared to TCD-managed patients. If the U.K. 
National Health Service were to reimburse hemodialysis at 
a uniform rate regardless of the type of vascular access, net 
1-year savings of £1200 per patient are estimated for 
individuals managed with the HeRO Graft. 
 
Cost-
effectiveness 
analysis 
Cost-effectiveness ratio 
(CER) 
or incremental cost 
effectiveness ratio 
(ICER) 
Measures the additional 
cost per unit of benefit 
and allows drawing a 
“health economical 
ranking” of different 
procedures 
Applicable only if the 
compared 
interventions use a 
common health 
outcome (unit of 
effectiveness)  
 
The cost-effectiveness of tumor-treating fields 
therapy in patient with newly diagnosed 
glioblastoma [34] 
Tumor-treating fields (TTF) therapy consists of a medical 
device that creates low-intensity and intermediate-
frequency electric fields with an antimitotic effect on 
glioblastoma cells. According to the preliminary results of a 
RCT, the addition of TTF therapy to the standard protocol 
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Analyses the 
interventions in terms 
of quantity and not of 
quality of life. 
(radiotherapy combined with temozolomide) for newly 
diagnosed patients with glioblastoma resulted in a life 
expectancy of 22.08 months compared with 18 months after 
the conventional therapy strategy. The incremental 
effectiveness, expressed as life-years gained, was 4.08 
months in favor of  TTF strategy. The total costs, from a 
provider’s perspective, were € 243 141 for TTF and € 57 
665 for the standard therapy strategy. The incremental cost-
effectiveness (ICER) was thus € 549 909 per life-year 
gained (see text for the formula).  
Cost-utility 
analysis 
Cost-utility ratio (cost per 
QALYa, quality adjusted 
life years), 
 
 
 
Focuses on patient’s 
preference for being in a 
particular state of health 
 
Allows comparison 
between different 
treatments used in various 
stages of a disease with 
different unit of benefit 
 
Analyses the interventions 
in terms of both quality 
and quantity of life 
 
QALYs reflect the 
mean value of the 
general population, 
which might differ 
from the specific 
priorities of the 
individual patient 
 
Day care versus inpatient management of 
nausea and vomiting of pregnancy: cost utility 
analysis of a randomized controlled trial [34] 
Data were obtained from a recently published RTC to asses 
the cost-effectiveness of day care versus inpatient 
management of nausea and vomiting of pregnancy (NVP). 
Costs and outcomes were considered with the perspective of 
the health care provider and patients. The primary study 
outcome was the total number of inpatient nights related to 
nausea and vomiting. The median number of inpatient 
admissions were fewer for day care compared to inpatient 
management. The mean cost was € 985 per patient in day 
care management, and € 3837 per patient in inpatient 
management, considering both the health system and the 
patients’ perspectives. Thus, day care management is less 
costly. The QALYs estimated for day care and inpatient 
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Table 1. Characteristics of different methods for economic evaluation in health care.  
a QALY= utility value (from 0 to 1) multiplied with the length of time in that state 
 
 
Represents the best 
method to allocate 
resources from a fixed 
budget 
management were, respectively, 9.49 and 9.42. Thus, day 
care management is more cost effective. The cost-utility 
ratio (the cost of a treatment divided for QALYs generated 
from that treatment) for day care management is € 985 
/9.49= €103.79 per QALY, whereas for inpatient 
management is € 3837/9.42= €407.32 per QALY. 
